journal article·2020-04-10Open access

TB Elimination Requires Discovery and Development of Transformational Agents

Christian Lienhardt, Mario C. Raviglione

Applied Sciences· Volume 10· Issue 7

Abstract

The World Health Organization (WHO) End Tuberculosis (TB) Strategy has set ambitious targets to reduce 2015 TB incidence and deaths by 80% and 90%, respectively, by the year 2030. Given the current rate of TB incidence decline (about 2% per year annually), reaching these targets will require new transformational tools and innovative ways to deliver them. In addition to improved tests for early and rapid detection of TB and universal drug-susceptibility testing, as well as novel vaccines for improved prevention, better, safer, shorter and more efficacious treatments for all forms of TB are needed. Only a handful of new drugs are currently in phase II or III clinical trials, and a few combination regimens are being tested, mainly for drug-resistant TB. In this article, capitalising on an increasingly rich medicine pipeline and taking advantage of new methodological designs with great potential, the main areas where progress is needed for a transformational improvement of treatment of all forms of TB are described.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tuberculosis Research and Epidemiology · Biosimilars and Bioanalytical Methods · Mycobacterium research and diagnosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Unité Mixte Internationale TransVIHMI (UMI 233 IRD–U1175 INSERM, Université de Montpellier)-Institut de Recherche pour le Développement (IRD), 34000 Montpellier, France

Centre for Multidisciplinary Research in Health Science (MACH), Università di Milano, Milan, Italy and Global Studies Institute, Université de Genève, 1211 Genève, Switzerland

References (25)

Show source-provided references
1. World Health Organization (2014). Sixty-Seventh World Health Assembly WHA67.1, World Health Organization.
2. World Health Organization (2014). Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015, World Health Organization. Agenda item 12.1, 21 May 2014.
3. WHO’s End TB Strategy10.1016/S0140-6736(15)60570-0 ↗
4. World Health Organization (2019). Global Tuberculosis Report 2019, World Health Organization.
5. Styblo, K. (1991). Epidemiology of Tuberculosis, The Royal Netherlands Tuberculosis Association (KNCV).
6. Tuberculosis in Eskimos10.1016/0041-3879(76)90059-3 ↗
7. Tuberculosis: Advances and challenges in development of new diagnostics and biomarkers10.1016/S1473-3099(18)30111-7 ↗
8. (2020, March 30). Stop TB Partnership’s Working Group on New TB Drugs Clinical Pipeline. Available online: https://www.newtbdrugs.org/pipeline/clinical.
9. Eliminating human tuberculosis in the 21st century10.1098/rsif.2007.1138 ↗
10. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis10.1056/NEJMoa1909953 ↗
11. Treatment Action Group (2019). Tuberculosis Research Funding Trends 2005–2018, Treatment Action Group.
12. The Lancet Commission on TB (2019). Building a Tuberculosis-Free World: The Lancet Commission on Tuberculosis. Lancet.
13. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis10.1056/NEJMoa1901814 ↗
14. World Health Organization (2016). Target Regimen Profiles for TB Treatment: Candidates: rifampicin-Susceptible, Rifampicinresistant and pan-TB Treatment Regimens, World Health Organization.
15. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents10.3390/molecules19044380 ↗
16. Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery10.1128/mBio.00272-17 ↗
17. Shi-Yan Foo, C., Pethe, K., and Lupien, A. (2020). Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Appl. Sci., 10.10.3390/app10072339 ↗
18. Challenges in tuberculosis drug research and development10.1038/nm0307-290 ↗
19. Lienhardt, C., and Nahid, P. (2019). Advances in clinical trial design for development of new TB treatments: A call for innovation. PLoS Med., 16.10.1371/journal.pmed.1002769 ↗
20. Dooley, K.E., Hanna, D., Mave, V., Eisenach, K., and Savic, R.M. (2019). Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. PLoS Med., 16.10.1371/journal.pmed.1002842 ↗
21. Adaptive clinical trials in tuberculosis: Applications, challenges and solutions10.5588/ijtld.14.0988 ↗
22. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: A multi-arm, multi-stage randomised controlled trial10.1016/S1473-3099(16)30274-2 ↗
23. Phillips, P.P.J., Dooley, K.E., Gillespie, S.H., Heinrich, N., Stout, J.E., Nahid, P., Diacon, A.H., Aarnoutse, R.E., Kibiki, G.S., and Boeree, M.J. (2016). A new trial design to accelerate tuberculosis drug development: The Phase IIC Selection Trial with Extended Post treatment follow-up (STEP). BMC Med., 14.10.1186/s12916-016-0597-3 ↗
24. Davies, G., Hoelscher, M., Boeree, M., and Hermann, D. (2019). Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. PLoS Med., 16.10.1371/journal.pmed.1002851 ↗
25. Lienhardt, C., Nunn, A., Chaisson, R., Vernon, A.A., Zignol, M., Nahid, P., Delaporte, E., and Kasaeva, T. (2020). Advances in clinical trial design: Weaving tomorrow’s TB treatments. PLoS Med., 17.10.1371/journal.pmed.1003059 ↗